Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ABLS licenses IP from Harvard

22 Jun 2015 07:00

RNS Number : 7791Q
Allied Minds PLC
22 June 2015
 



 

Media Contact:

Christine Dunn

ArcPoint Strategic Communications

cdunn@arcpointstrategy.com

617.484.1660 x101

 

 

Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University

 

· Allied-Bristol Life Sciences (ABLS) has licensed intellectual property developed in Professor Malcolm Whitman's laboratory at Harvard.

· The intellectual property includes lead molecules and a differentiated mechanism to develop drugs for treating chronic fibrotic and autoimmune diseases.

 

Boston (June 22, 2015) - Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned by Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), today announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Whitman's lab at the Harvard School of Dental Medicine.

 

Malcolm Whitman, PhD, Professor of Developmental Biology, and Tracy Keller, PhD, an instructor in the Department of Developmental Biology, have identified the mechanism of action behind a known natural product, halofuginone (HF). HF is a chemical compound based on an active ingredient in the root of the blue evergreen hydrangea (Dichroa febrifuga), which has been used in traditional Chinese medicine for centuries.

 

Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children's Hospital, Professor Whitman's lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction (AAR) response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases.

 

 "Our research is at the right stage for an infusion of resources and expertise to accelerate its progression," said Dr. Whitman. "We look forward to seeing the development of lead compounds from our laboratories into novel therapeutics for the treatment of fibrotic disease, and potentially other indications."

 

"The work done by Whitman and Keller is a terrific example of a promising early-stage therapeutic application that has the potential to make a significant difference to patients," said Satish Jindal, Chief Executive Officer of ABLS. "We are pleased to support this project through the next phase of drug discovery to identify a candidate for clinical development. This is a great example of the type of university research that ABLS looks for, where our expertise and experience can accelerate bringing new therapies to patients that need them."

 

The licensing agreement with Harvard's Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitman's lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.

 

For more information about Allied-Bristol Life Sciences, please visit www.ablifescience.com.

 

About Allied-Bristol Life SciencesAllied-Bristol Life Sciences (ABLS) is a jointly owned enterprise between Allied Minds and Bristol-Myers Squibb Co. Based upon compelling biological discoveries and insights from scientists at leading U.S. research institutions, ABLS identifies, sources and de-risks promising, early-stage therapeutic opportunities, from discovery through pre-clinical development, in key therapeutic areas, including fibrosis, cardiovascular diseases, oncology, immunology, virology and genetically defined diseases. For more information, visit www.ablifescience.com.

 

About Harvard University's Office of Technology Development

Harvard's Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. Harvard OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. The mission of Harvard OTD is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products that are available and beneficial to society. For more information, please visit http://otd.harvard.edu.

 

About Allied MindsAllied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com

 

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

Allied Minds Forward-Looking StatementThis press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the licensing agreement mentioned in this release will lead to identifying a pre-clinical candidate. Nor is there any guarantee that if one is identified, it will be successfully developed for or approved for any of the indications described in this release. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2014 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUASRRVAANUUR
Date   Source Headline
5th Jun 20204:40 pmRNSSecond Price Monitoring Extn
5th Jun 20204:35 pmRNSPrice Monitoring Extension
4th Jun 20207:00 amRNSAnnual Financial Report
21st May 20204:41 pmRNSSecond Price Monitoring Extn
21st May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:01 amRNSBlock listing Interim Review
11th May 20207:00 amRNSBlock listing Interim Review
27th Apr 20202:20 pmRNSDisclosure of Rights Attaching to Equity Shares
22nd Apr 20209:00 amRNSNotice of results - update
21st Apr 20207:00 amRNSFederated Wireless raises $13.7m
15th Apr 20204:40 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
3rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
3rd Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:47 pmRNSHolding(s) in Company
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:38 pmRNSPrice Monitoring Extension
23rd Mar 20205:04 pmRNSHolding(s) in Company
19th Mar 20205:38 pmRNSHolding(s) in Company
18th Mar 202010:00 amRNSNotice of results - update
13th Mar 20205:24 pmRNSHolding(s) in Company
11th Mar 20201:05 pmRNSFederated Wireless Extends Spectrum Controller
10th Mar 20207:00 amRNSDirectorate Changes
20th Feb 20209:40 amRNSFederated partners in UK 5G New Thinking project
18th Feb 20201:28 pmRNSFederated selects AWS as preferred cloud provider
18th Feb 20201:22 pmRNSFederated brings 4G/5G private networks to US
17th Feb 20205:20 pmRNSHolding(s) in Company
7th Feb 202010:00 amRNSNotice of Full-Year Results
3rd Feb 20207:00 amRNSTotal Voting Rights
16th Jan 20207:00 amRNSSpecial Dividend Declaration
15th Jan 20202:28 pmRNSBoeing HorizonX & BridgeComm pioneer optical mesh
2nd Jan 20202:53 pmRNSTotal Voting Rights
18th Dec 20193:31 pmRNSDirector/PDMR Shareholding
11th Dec 20193:13 pmPRNCrystal Amber withdraws requisition of Allied Minds
11th Dec 20197:00 amRNSBoard changes and restructuring initiatives
2nd Dec 20195:40 pmRNSTotal Voting Rights
28th Nov 20193:02 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:26 pmRNSHolding(s) in Company
20th Nov 201911:27 amRNSHolding(s) in Company
15th Nov 201910:45 amRNSDirector/PDMR Shareholding
13th Nov 201910:11 amRNSHolding(s) in Company
11th Nov 201910:41 amRNSBlock Listing Six-Monthly Return
11th Nov 201910:15 amRNSBlock Listing Six-Monthly Return
8th Nov 20192:31 pmRNSCompletion of Disposal
7th Nov 20193:39 pmRNSHolding(s) in Company
6th Nov 201912:34 pmRNSResults of General Meeting
5th Nov 201912:02 pmRNSPrice Monitoring Extension
22nd Oct 20194:53 pmRNSHolding(s) in Company
17th Oct 20195:06 pmRNSPublication of Circular
17th Oct 20191:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.